10-Q: Salarius Pharma Q2 Loss Narrows Amid Decoy Merger & Nasdaq Delisting Fight

Salarius Pharmaceuticals reported a reduced net loss in Q2 2025, driven by cost-cutting, as it navigates a critical merger with Decoy Therapeutics and ongoing Nasdaq listing compliance challenges.

Summary

• Net loss for the three months ended June 30, 2025, was $957,825, a decrease from $1,424,433 in the same period of 2024.
• Net loss for the six months ended June 30, 2025, was $2,667,358, down from $3,139,723 in the prior year period.
• Research and development expenses significantly decreased to $116,383 in Q2 2025 from $214,447 in Q2 2024, and to $191,915 for the six months from $457,449, primarily due to cost-saving measures and curtailed sponsored clinical trials.
• General and administrative expenses also decreased to $849,182 in Q2 2025 from $1,253,070 in Q2 2024, and to $2,492,345 for the six months from $2,781,683.
• Cash and cash equivalents stood at $794,886 as of June 30, 2025, down from $2,434,528 at December 31, 2024.
• Stockholders' equity was a deficit of $829,724 as of June 30, 2025, compared to a positive $1,511,695 at December 31, 2024.
• The company is pursuing a merger with Decoy Therapeutics Inc., with Salarius legacy stockholders' ownership in the combined company reduced from 14.1% to 7.6% due to valuation adjustments in the merger agreement.
• Salarius faces Nasdaq delisting for failing to meet the $1.00 minimum bid price and $2.5 million stockholders' equity requirements, but has received extensions until mid-August 2025 for equity and late August 2025 for bid price.
• Subsequent to June 30, 2025, the company raised $3.8 million through an Equity Line of Credit (ELOC) agreement, bringing current cash to approximately $3.4 million and stockholders' equity above $2.5 million as of the filing date.

Sentiment

Score: 3

Explanation: The company faces severe financial distress, including a going concern warning and Nasdaq delisting threats. While cost-cutting and a subsequent capital raise offer a temporary reprieve and the merger provides a potential path forward, the significant shareholder dilution and ongoing uncertainties surrounding the merger and long-term funding indicate a highly precarious situation. The reduced net loss is primarily due to curtailed R&D, not revenue generation.

Positives

• Reduced net loss for both the three and six months ended June 30, 2025, compared to the prior year periods, indicating improved cost control.
• Significant reduction in Research and Development expenses due to implemented cost-saving initiatives and the curtailment of sponsored clinical trials.
• Decreased General and Administrative expenses, reflecting successful cost-cutting measures in personnel, insurance, and facility costs.
• Successful appeal to Nasdaq resulted in extensions to regain compliance with listing rules, providing additional time to execute strategic plans and avoid immediate delisting.
• Successful capital raise of $3.8 million subsequent to quarter-end through the Equity Line of Credit, improving the cash position to approximately $3.4 million and stockholders' equity to over $2.5 million, addressing immediate liquidity and Nasdaq compliance concerns.

Negatives

• Continued accumulated deficit, reaching $84,590,976 as of June 30, 2025, indicating a history of unprofitability.
• Stockholders' equity was a deficit of $829,724 as of June 30, 2025, falling below Nasdaq's $2.5 million requirement, although subsequently remedied by capital raise.
• Cash and cash equivalents significantly decreased to $794,886 as of June 30, 2025, indicating high cash burn prior to the subsequent capital raise.
• Substantial dilution for Salarius legacy stockholders in the proposed merger with Decoy Therapeutics, with their ownership reduced from 14.1% to 7.6% of the combined company.
• Ongoing Nasdaq delisting threat due to non-compliance with minimum bid price and stockholders' equity requirements, despite granted extensions.
• The company has no products approved for commercial sale and has not generated any revenue from product sales since inception.
• Substantial doubt exists regarding the company's ability to continue as a going concern without additional capital or the successful completion of the merger.
• Curtailed sponsored clinical trials, with an intent to rely on investigator-initiated trials, which may slow the pace of drug development.

Risks

• Inability to regain compliance with Nasdaq listing standards, which would lead to delisting and severely harm the liquidity and market price of common stock.
• Failure to successfully complete the merger with Decoy Therapeutics or obtain additional financing in the near term, which could force the company to cease operations, liquidate assets, and pursue dissolution.
• Stockholders may not realize a benefit from the merger commensurate with the ownership dilution they will experience.
• The merger consideration may have greater or lesser value at the closing of the merger than at the time the merger agreement was signed.
• Conditions to the merger, including the consummation of a Qualified Financing with aggregate minimum proceeds of at least $6.0 million, may not be met.
• The market price of common stock may decline following the merger.
• Restrictions in the merger agreement may prevent the company from entering into a business combination with another party at a favorable price.
• The combined company may not be able to raise additional funds when necessary and/or on acceptable terms.
• Unanticipated difficulties with preserving capital or unanticipated charges not currently contemplated that may occur as a result of cost savings plans.
• Uncertainties about the paths of drug programs and the ability to evaluate and identify a path forward given limited financial, personnel, and operating resources.
• The adequacy of capital to support future operations.
• Fluctuations in operating results.
• Potential for the company to be treated as a public shell under Nasdaq rules, leading to delisting proceedings or additional and more stringent listing criteria.
• If delisted, securities may qualify for trading over-the-counter, which generally involves lesser requirements but also reduced liquidity and market price.
• Risk of litigation or other claims related to a dissolution and liquidation if the company is forced to wind down operations.
• Future funding requirements are uncertain and depend on many factors, including the pace and results of clinical development activities and market conditions.
• The amounts available under the shelf registration statement on Form S-3 are significantly limited as long as the public float remains below $75 million, restricting access to meaningful funding through this mechanism.

Future Outlook

The company anticipates continued operating losses and requires substantial additional capital within the next several months to fund operations beyond the second quarter of 2026. The successful completion of the merger with Decoy Therapeutics, including a Qualified Financing of at least $6.0 million, is critical for its continued operations and Nasdaq listing compliance. Future funding requirements are highly dependent on the strategic alternatives process, ability to raise additional capital on commercially reasonable terms, and the pace of clinical development activities. If the merger does not close or additional capital is not secured, the company will be forced to cease operations and liquidate assets.

Management Comments

• We believe that there is presently insufficient funding available to allow us to continue our current and planned clinical programs for a period exceeding 12 months from the date of this filing with the SEC.
• We will continue to require substantial additional capital to continue our operations and any clinical development activities that we determine to advance and will need such additional capital within the next several months to continue to fund our operations beyond the second quarter of 2026.
• We have curtailed expenses and plan to use our two remaining full time employees and consultants to continue our operations.
• We have approximately $3.4 million in cash and cash equivalents as of the date of this report and we believe such amount is sufficient to fund our current and restructured operations into the second quarter of 2026.
• Our stockholders' equity balance was $-0.8 million at June 30, 2025, and is above $2.5 million as of this report date.

Industry Context

Salarius Pharmaceuticals operates in the highly capital-intensive and high-risk clinical-stage biopharmaceutical sector, characterized by significant R&D expenditures, long development timelines, and reliance on external funding. The company's strategic review and proposed merger with Decoy Therapeutics reflect a common trend among smaller biotechs facing liquidity challenges and seeking to combine resources or pivot strategies to survive and advance pipelines. The ongoing Nasdaq delisting issues highlight the stringent financial and operational requirements for public companies in this space, where maintaining market capitalization and equity standards is crucial for investor confidence and access to capital markets. The curtailment of sponsored clinical trials and reliance on investigator-initiated studies indicate a shift towards a more capital-efficient, albeit potentially slower, development model, a common adaptation for companies with limited financial runways.

Comparison to Industry Standards

• The company's accumulated deficit of $84.6 million and recurring operating losses are typical for clinical-stage biopharmaceutical companies that have not yet commercialized products.
• The cash position of $0.79 million at quarter-end, and even the improved $3.4 million post-quarter, is very low compared to industry peers that typically maintain cash runways of 12-24 months to fund ongoing R&D and operational expenses. Many small-cap biotechs often aim for at least $10-20 million in cash to support a year of operations.
• The negative stockholders' equity of $(0.83) million at June 30, 2025, is significantly below the Nasdaq minimum requirement of $2.5 million, indicating severe financial distress. While temporarily remedied by subsequent capital raise, this is a critical red flag.
• The substantial dilution of legacy shareholder ownership from 14.1% to 7.6% in the Decoy merger is a significant concession, reflecting the company's weak negotiating position and urgent need for a strategic transaction to avoid liquidation. This level of dilution is often seen in distressed asset sales or reverse mergers where the acquiring entity brings the primary value.
• The reliance on an Equity Line of Credit (ELOC) and At-the-Market (ATM) offerings for capital is a common, but often dilutive, financing strategy for small-cap biotechs struggling to raise funds through traditional equity offerings.
• The curtailment of sponsored clinical trials and reliance on investigator-initiated studies for SP-2577 and SP-3164 is a cost-saving measure, but it contrasts with more well-funded peers who actively manage and fund their clinical pipelines to accelerate development.

Management Changes

Corporate Governance

Legal Proceedings

• No material legal proceedings are currently a party to on the date of this report.

Related Party Transactions

• The company has a license agreement with the University of Utah Research Foundation, under which it acquired an exclusive license to an epigenetic enzyme lysine specific demethylase 1 (LSD1) in 2011. In exchange, the company issued 2% equity ownership and agreed to revenue sharing rights on any resulting products or processes and milestone payments based upon regulatory approval and commercial sale.

Stakeholder Impact

• Shareholders face significant dilution from the proposed merger and ongoing capital raises. There is a substantial risk of losing all or a significant portion of their investment if the company liquidates. Potential for delisting could severely impact liquidity and market price of shares.
• Employees have experienced significant reduction in operating personnel as part of cost-saving measures, with only two full-time employees remaining, indicating job insecurity.
• Creditors face increased risk due to the company's going concern warning and historical low cash balance, although the recent capital raise provides a temporary buffer.
• Patients and the research community may experience slower development of potential cancer treatments (SP-3164, SP-2577) due to the curtailment of sponsored clinical trials and reliance on investigator-initiated studies.

Next Steps

• Complete the merger with Decoy Therapeutics Inc., contingent on a Qualified Financing of at least $6.0 million and continued Nasdaq listing.
• Regain compliance with Nasdaq's Equity Standard by mid-August 2025.
• Regain compliance with Nasdaq's Minimum Bid Price Requirement by late August 2025.
• File an initial listing application with Nasdaq following the Qualified Financing and Merger Closing.
• Seek stockholder approval for the conversion of Preferred Stock into common stock following Nasdaq's approval of the initial listing application.
• Register the issuance of common stock underlying the Preferred Stock within 60 days of the Merger Closing.
• Continue to rely on clinical trial data from the investigator-initiated clinical trial conducted by MD Anderson Cancer Center for SP-2577 and SP-3164.
• Potentially pursue further capital raises through equity or debt instruments, or new collaborations, if the merger does not close.
• Implement a reverse stock split (ratio in the range of 1:4 to 1:40) as approved by stockholders, if determined by the Board.

Key Dates

Recommendation

The company faces existential threats, including a 'going concern' warning and persistent Nasdaq delisting issues. While recent capital raises and extensions from Nasdaq offer a temporary lifeline, the underlying financial health remains extremely precarious. The proposed merger with Decoy Therapeutics involves severe dilution for existing shareholders (from 14.1% to 7.6% ownership), indicating a distressed asset sale. The company has no revenue, continues to incur significant losses, and has curtailed its own clinical trials, relying on external investigator-initiated studies. The long-term viability is highly uncertain, contingent on a complex merger and further capital raises in a challenging market. The risk of total loss of investment is substantial, making it an unattractive proposition for investors.

Keywords

Biopharmaceutical, Cancer Treatment, Clinical Stage, Nasdaq Listing, Delisting Risk, Merger Agreement, Decoy Therapeutics, Strategic Alternatives, Going Concern, Equity Line of Credit, Reverse Stock Split, SP-3164, Seclidemstat, Oncology, Financial Reporting, Liquidity, Capital Raise, Shareholder Dilution